☆ 4.7 Article

Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

Summary: In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Tyler N. Starr et al.

Summary: Research has found that mutations in the receptor binding domain (RBD) of SARS-CoV-2 may potentially escape the action of the REGN-COV2 cocktail, providing important information for interpreting mutations observed during viral surveillance.

SCIENCE (2021)

添加到收藏夹

Review Microbiology

Understanding the Impact of Resistance to Influenza Antivirals

Edward C. Holmes et al.

Summary: Influenza poses a significant burden on society and healthcare systems. Antiviral resistance can lead to uncertainty among prescribers and policy makers. Antiviral treatment generally provides clinical benefit and resistant viruses are usually associated with reduced fitness.

CLINICAL MICROBIOLOGY REVIEWS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

添加到收藏夹

Article Microbiology

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Pengfei Wang et al.

Summary: The emerging Brazilian variant P.1 shows increased resistance to antibody neutralization, posing a threat to current antibody therapies, but has less impact on the effectiveness of protective vaccines.

CELL HOST & MICROBE (2021)

添加到收藏夹

Review Virology

Neutralizing Antibody Therapeutics for COVID-19

Aeron C. Hurt et al.

Summary: The emergence of SARS-CoV-2 and the subsequent COVID-19 pandemic have created an urgent need for effective therapeutic strategies. Neutralizing antibodies have shown potential in treating and preventing COVID-19, but their efficacy in severe cases remains varied. Treatment may lead to the formation of antiviral resistant escape mutants, highlighting the importance of exploring strategies to minimize risk.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Richard Copin et al.

Summary: Monoclonal antibodies against SARS-CoV-2 are clinically validated therapeutic options against COVID-19. Studies show that non-competing antibody combinations in REGEN-COV provide protection against all current variants of concern and prevent the emergence of new variants.

CELL (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2

Pravas Kumar Baral et al.

Summary: Researchers worldwide are working on developing prophylactic and therapeutic interventions to combat the COVID-19 crisis, with a focus on antibody-based therapies targeting the viral spike protein, particularly monoclonal antibodies.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Delphine Planas et al.

Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Rita E. Chen et al.

Summary: Cell culture experiments showed reduced or abrogated neutralizing activity of monoclonal antibodies against SARS-CoV-2 variant strains, but low prophylactic doses of antibody combinations protected against infection in vivo without resistance emergence. Higher doses of several monoclonal antibody cocktails also provided protection against viruses with a B.1.351 spike gene in vivo. Many antibody products with Emergency Use Authorization should therefore retain substantial efficacy against prevailing variant strains of SARS-CoV-2.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Medicine, General & Internal

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis

Reed A. C. Siemieniuk et al.

Summary: For non-severe covid-19 patients, monoclonal antibodies like casirivimab-imdevimab may reduce hospitalization, while convalescent plasma, IVIg, and other antibody and cellular interventions may not provide meaningful benefits. In severe or critical covid-19 patients, only casirivimab-imdevimab has shown a potential reduction in mortality risk, with other interventions showing no significant impact on outcomes.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial

Huijie Bian et al.

Summary: The study found that blocking CD147 with anti-CD147 antibody could suppress SARS-CoV-2 replication, and meplazumab may effectively prevent infection in COVID-19 patients. The safety and efficacy of meplazumab were demonstrated in healthy volunteers and COVID-19 patients, indicating its potential in treating COVID-19 pneumonia.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Dawei Wang et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Immunology

Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection

Yeming Wang et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Medicine, General & Internal

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chaolin Huang et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Critical Care Medicine

COVID-19 with Different Severities: A Multicenter Study of Clinical Features

Yun Feng et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Safiya Richardson et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Annemarie B. Docherty et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

B. Cao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

A. B. Cavalcanti et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al.

SCIENCE (2020)

添加到收藏夹

Article Critical Care Medicine

Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study

John H. Beigel et al.

LANCET RESPIRATORY MEDICINE (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)

William F. Dall'Acqua et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.